This interactive course is made up of 11 modules illustrating the key pharmaceutical supply chain stakeholders and their functions as products move from the manufacturer to the customer.
(Webinar Held: May 4, 2021) HDA hosts a virtual discussion with four leaders driving diversity, equity and inclusion (DE&I) efforts within the healthcare supply chain.
(Webinar Held: January 27, 2021) Join HDA and The Hill for a virtual conversation between policymakers, leaders in the pharmaceutical and distribution industries and public health experts on how vaccines...
The 91st Edition HDA Factbook (2020–2021) provides comprehensive distribution performance metrics that highlight growth and trends in the pharmaceutical industry.
NON - MEMBER PRICE: $0.00 | MEMBER PRICE: $0.00
These guidelines educate trading partners across the healthcare supply chain in the processes used for the negotiation and administration of contracts, as well as the submission, validation and reconciliation...
PRICE : $0.00 - $75.00
This white paper provides a brief overview of the pharmaceutical supply chain, product supply issues and current processes that can result in product shortages.
PRICE : $0.00 - $0.00
Developed by HDMA’s Returns Task Force, this summary reports the volume and average dollar value of returned prescription and over-the-counter products processed by reverse logistics providers.
PRICE : $0.00 - $495.00
Developed by the HDMA Returns Task Force, this article identifies ways to reduce unsalable returns and reduce supply chain waste.
Developed by HDMA’s Returns Task Force, these voluntary guidelines provide insights into industry recall and withdrawal practices, as well as strategies for manufacturers and distributors to effectively...
Trading partners may use this sample returned goods debit memo template to clearly convey the pertinent information about returned pharmaceuticals and facilitate the credit reconciliation process.
This report focuses on the opportunities to improve communications between trading partners as a branded pharmaceutical product nears the end of its patent protection to better manage inventory and reduce...
Developed by HDMA’s Returns Task Force, this report addresses key issues and recommends process improvements for returned or unsalable healthcare products.
These recommendations suggest practices that a pharmaceutical entity could employ to identify and help minimize the risks associated with storing pharmaceutical products.
Violent attacks are increasing in the last mile for pharmaceutical supply chain distribution. These suggested guidelines offer companies seeking to strengthen their in-transit security program a directed...